Are you full of ideas and impatient for action to translate the opportunities of the genomic age into better therapeutics and diagnostics? Do you have a truly collaborative mindset and enjoy teamwork across disciplines? Do you have an inclusive and open personality that cherishes being a scientist within a broader cultural and social context? CeMM, the Center for Molecular Medicine of the Austrian Academy of Sciences, is one of the best places you should consider to advance your basic, medical-oriented research. We are a group of 130 scientists from 34 nations working at the interface of basic research and medicine in the areas of inflammation/infection/immunity, cancer and metabolic disorders. We are situated in a beautiful, bright and perfectly designed building (inaugurated in 2011), with outstanding design and state-of-the-art laboratories, strategically located next to one of the world’s largest research hospital. Vienna is one of Europe’s most fascinating capitals, with world-best quality of life, legendary music and culture. CeMM has been voted best place to work in academia in a 2012 survey by The Scientist. CeMM is an equal opportunity employer. The official language at CeMM is English. Within our short life, based on our super-cooperative research mode and –omics technologies, we have already identified the missing cancer gene in myeloproliferative neoplasms (Klampfl et al. NEJM 2013), a new cancer pathway with a new drug (Huber et al. Nature 2014), as well as the molecular basis for acute macular degeneration (Weismann et al. Nature 2011). The total number of publications within the last three years was 158, among more than half, 82 papers have been published in journals with an impact factor > 10 (Institute is the affiliation of the last author). To complement and strengthen the current faculty, CeMM is looking for outstanding individuals who work on an exciting problem of molecular medicine, preferably but not exclusively pertaining to Innate Immunity, Infection Biology, Inflammation, Hematopoiesis, Hematological Malignancies, Genome Integrity, Blood, Vascular Disorders or Metabolic Disorders. Approaches that we are particularly interested in are: Systems Biology, Bioinformatics, Immunotherapy, Genomics, Epigenetics, Metabolomics, Chemical Biology, High-Content Screening, Single-Cell Technologies.